ArticleESMO open2022

Risk of thromboembolism in non-small-cell lung cancers patients with different oncogenic drivers, including ROS1, ALK, and EGFR mutations.

H-Y Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.